Page 7 - Johnson & Johnson

J&J loses bid to overturn baby powder verdict, but damages cut to $2.12 bn

The Missouri Court of Appeals lowered the original $4.69 billion verdict from July 2018 after dismissing claims by some of the 22 women and their families who had sued

J&J sets aside fairness business to stand with #BlackLivesMatter movement

Now with J&J taking its brand out of the game, other brands have a larger slice of the pie to carve out, but is there a risk in doing that?

J&J to begin human trials of Covid-19 vaccine in second half of July

The company has already signed deals with the US government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021

Johnson & Johnson to stop selling talc-based baby powder in US, Canada

J&J faces about 19,400 cases alleging its talcum powder caused users to develop ovarian cancer, through use for feminine hygiene, or mesothelioma, a cancer that strikes the lungs and other organs

J&J to stop selling baby powder in US, Canada after portfolio reassessment

J&J faces more than 16,000 lawsuits from consumers claiming its talc products, including Johnson's Baby Powder, caused their cancer

Johnson & Johnson expects human trial of its Covid-19 vaccine by September

Through a partnership, the Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson together have committed more than $1 billion of investment to co-fund vaccine research

Johnson & Johnson says no evidence of HIV drug working against Coronavirus

The company said it was aware that HIV treatments are being considered as options to treat patients diagnosed with COVID-19, a disease caused by the coronavirus

J&J sees high demand for consumer products as Coronavirus spreads

J&J said majority of its global medical device manufacturing was running at or near normal capacity, and that it does not expect the outbreak to cause any disruptions to its supply of medicines.

J&J ordered by Florida jury to pay $9 million in talc-cancer case

The talc litigation may eventually cost the company as much as $10 billion, according to Bloomberg Intelligence

S P Jain Global bags 50% international offers, top offer at Rs 45 lakh

Consulting emerges as top recruiting sector, with 24% placement offers, followed by logistics & supply chain at 17%, and IT at 16%

J&J's own expert working for FDA found asbestos in baby powder sample

(Reuters) - Ever since Johnson & Johnson disclosed this month that a government test had turned up asbestos in its Baby Powder, the company has attacked the validity of the result.

Johnson & Johnson to expand its anti-TB programme in India

Programme aims to broaden access to treatment for multidrug-resistant strain, improve detection, build critical health systems, and raise awareness about TB at community level

J&J asked to pay $8 billion over side effects of antipsychotic drug

NEW YORK (Reuters) - Johnson & Johnson must pay $8 billion (6.6 billion pounds) in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.

US judge fines Johnson & Johnson $572 mn for fuelling opioid epidemic

(Reuters) - An Oklahoma judge on Monday found Johnson & Johnson liable for fuelling an opioid epidemic in the state by deceptively marketing painkillers, and ordered the drugmaker to pay damages of $572 million.

J&J pays Rs 25 lakh each to three victims in UP for faulty hip implants

Pharmaceutical Major Johnson & Johnson said it has paid Rs 25 lakh each to three victims of its faulty acetabular surface replacement (ASR) hip implants in Uttar Pradesh. According to Uttar Pradesh Drug Licensing and Control officer A K Jain, the company has given compensation to three patients who had undergone revision surgeries for the faulty implants made by the company. The Delhi High Court had in May directed Johnson and Johnson to make an interim payment of Rs 25 lakh each to the 67 patients who have undergone revision surgeries. Jain said the Uttar Pradesh Drug Licensing and Control Authority was promptly following such complaints.

J&J denies withholding interim compensation for faulty hip implants

However, the central government told the court that the company till date has paid the interim compensation to only 67 patients out of the over 4,700 persons

J&J to pay Rs 25 lakh each to 67 victims of faulty ASR hip implants

J&J says it will pay other patients only if they fulfil criteria set by company

J&J's largest India plant idle for 3 yrs, hurts govt's employment campaign

The groundbreaking of the J&J facility in Telangana's Penjerla, its third in the country, was carried out with much fanfare in 2014.

No formaldehyde in baby shampoo: J&J rejects Rajasthan govt report

Johnson & Johnson has strongly rejected findings of a Rajasthan government laboratory showing presence of "harmful" chemicals in the US-based company's baby shampoo, a popular product in India. Based on the report of the Drug Testing Laboratory in Jaipur, the National Commission for Protection of Child Rights (NCPCR) has written to the chief secretaries of all states and Union Territories asking them to stop sale of Johnson & Johnson's (J&J) baby shampoo and remove it from the stocks. The NCPCR said the test report found presence of formaldehyde in J&J's baby shampoo. The company, in a statement, said it has not received any direction to stop the sale of its shampoo and that it was not accepting the interim results of the laboratory tests which were based on "unknown and unspecified" methods. India is a major market for J&J globally, and its share in the country's Rs 4,000-crore baby care market is nearly three-fourths. "We will await the results and conclusions of

Child rights body asks states to stop sale of Johnson's baby shampoo

Its sample was found to be of substandard quality in a lab test